Crinetics Pharmaceuticals (CRNX)

Executive Summary

Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for rare endocrine diseases and endocrine-related tumors. Its lead asset, paltusotine (PALSONIFY™), is a novel somatostatin receptor type 2 agonist targeting acromegaly and neuroendocrine tumors. With two ongoing Phase 3 trials in acromegaly (NCT05192382, NCT04837040) expected to read out in 2027-2028, paltusotine has the potential to replace injectable peptide therapies. Additionally, atumelnant (CRN04894) is in Phase 1/2 for Cushing syndrome, with proof-of-concept data anticipated in 2026, and CRN09682 recently entered Phase 1/2 for neuroendocrine neoplasms. Crinetics' proprietary GPCR platform enables selective, nonpeptide compounds, positioning the company to address significant unmet needs in endocrinology. The recent completion of a Phase 2 trial in carcinoid syndrome (NCT05361668) further supports paltusotine's broad utility. With a strong cash position and multiple value-driving catalysts, Crinetics is a high-conviction investment opportunity in the rare disease space.

Upcoming Catalysts (preview)

• Q3 2026Paltusotine Phase 3 ACROBAT Edge topline data (NCT04837040)85% success
• Q4 2026Atumelnant Phase 1/2 Cushing syndrome topline results (NCT05804669)70% success
• Q2 2027CRN09682 Phase 1/2 initial safety/efficacy data (NCT07129252)60% success